<p>Procyon Advisors LLC 在第一季度购买了 Cencora, Inc. (NYSE:COR - 免费报告) 的新股份，根据其最近向证券交易委员会 (SEC) 提交的 13F 文件。该公司购买了 5,951 股公司股票，价值约为 1,655,000 美元。</p>
<ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
<p>其他机构投资者最近也买卖了该公司的股票。Whittier Trust Co. 在第四季度将其在 Cencora 的持股增加了 0.6%。Whittier Trust Co. 目前拥有 7,856 股公司股票，价值 1,765,000 美元，在此期间又增持了 44 股。Shepherd Financial Partners LLC 在第四季度将其在 Cencora 的持股增加了 0.9%。Shepherd Financial Partners LLC 目前拥有 5,441 股公司股票，价值 1,223,000 美元，在上个季度又购买了 46 股。WASHINGTON TRUST Co 在第四季度将其在 Cencora 的持股增加了 37.7%。WASHINGTON TRUST Co 目前拥有 168 股公司股票，价值 38,000 美元，在上个季度又购买了 46 股。JFS Wealth Advisors LLC 在第四季度将其在 Cencora 的持股增加了 63.0%。JFS Wealth Advisors LLC 目前拥有 119 股公司股票，价值 27,000 美元，在此期间又购买了 46 股。最后，Cullen Frost Bankers Inc. 在第四季度将其在 Cencora 的持股增加了 1.1%。Cullen Frost Bankers Inc. 目前拥有 4,463 股公司股票，价值 1,003,000 美元，在上个季度又购买了 47 股。97.52% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>多家券商对 COR 发布了报告。Robert W. Baird 将 Cencora 的目标价格从 314.00 美元上调至 350.00 美元，并在 5 月 8 日的报告中给予该公司 “跑赢大盘” 的评级。花旗集团将 Cencora 的目标价格从 330.00 美元上调至 355.00 美元，并在 5 月 8 日的研究报告中给予该公司 “买入” 评级。美国银行将 Cencora 的目标价格从 270.00 美元上调至 285.00 美元，并在 4 月 11 日的研究报告中给予该股票 “中性” 评级。摩根士丹利在 4 月 15 日的研究报告中设定了 Cencora 的 288.00 美元价格目标。最后，富国银行将 Cencora 的评级从 “等权重” 上调至 “超配”，并在周二将该股票的目标价格从 274.00 美元上调至 337.00 美元。一位分析师对该股票给予了持有评级，十位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价格为 306.91 美元。</p>
<ul>
<li>Walgreens 股票上涨：WBA 可能是强劲买入的 4 个理由</li>
</ul>
<p><strong>阅读我们关于 COR 的最新报告</strong></p>
<h2>Cencora 股票上涨 0.2%</h2>
<p>NYSE:COR 的股票在周五开盘价为 289.01 美元。该公司的速动比率为 0.54，流动比率为 0.92，债务与股本比率为 16.40。该公司的市值为 560.2 亿美元，市盈率为 41.11，市盈率/增长比率为 1.31，贝塔值为 0.58。Cencora, Inc. 的 52 周低点为 218.65 美元，52 周高点为 309.35 美元。该股票的 50 日简单移动平均线为 286.29 美元，200 日简单移动平均线为 260.15 美元。</p>
<ul>
<li>Teva Pharma 是重新崛起的仿制药的投资方式</li>
</ul>
<p>Cencora (NYSE:COR - 获取免费报告) 最近在 5 月 7 日星期三发布了其财报。该公司报告每股收益 (EPS) 为 4.42 美元，超过分析师共识预期的 4.07 美元，超出 0.35 美元。Cencora 的净利润率为 0.46%，股本回报率为 328.62%。该公司在本季度的收入为 755 亿美元，而分析师预期为 754.1 亿美元。在去年同期，该公司每股收益为 3.80 美元。该公司的季度收入同比增长 10.3%。作为一个整体，股票研究分析师预测 Cencora, Inc. 在当前财政年度将发布 15.37 美元的每股收益。</p>
<h2>Cencora 宣布分红</h2>
<p>该公司最近还宣布了季度分红，已于 6 月 2 日星期一支付。5 月 16 日星期五的登记股东获得了 0.55 美元的分红。除息日期为 5 月 16 日星期五。这代表着每年 2.20 美元的分红，收益率为 0.76%。Cencora 的分红支付比率 (DPR) 目前为 25.52%。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，首席会计官 Lazarus Krikorian 于 3 月 10 日星期一出售了 2,000 股公司股票。股票以平均价格 260.06 美元出售，总交易额为 520,120.00 美元。交易完成后，首席会计官现在拥有 20,154 股公司股票，价值 5,241,249.24 美元。这代表着其持股减少了 9.03%。该交易已在向 SEC 提交的法律文件中披露，文件可通过此链接获取。此外，董事长 Steven H. Collis 于 4 月 22 日星期二出售了 14,579 股公司股票。股票以平均价格 281.81 美元出售，总交易额为 4,108,507.99 美元。交易完成后，董事长现在拥有 315,913 股公司股票，价值约 89,027,442.53 美元。此次交易使其持股减少了 4.41%。该交易的披露信息可以在此处找到。内部人士在上个季度共出售了 40,253 股公司股票，价值 11,102,417 美元。10.80% 的股票目前由公司内部人士持有。</p>
<h2>Cencora 公司简介</h2>
<p>(免费报告)</p>
<p>Cencora, Inc. 采购和分销药品。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代地点药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配备和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Cencora</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>大规模石油供应下降可能意味着这三只能源股的上涨空间</li>
<li>经纪排名在股票选择中的重要性</li>
<li>三只股票获得分析师罕见的双重升级</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>这家银行巨头刚刚获得了 90 美元的目标价上调</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
<p>在你考虑 Cencora 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cencora 并不在名单上。</p>
<p>虽然 Cencora 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Procyon Advisors LLC 在第一季度收购了 5,951 股 Cencora, Inc.（纽约证券交易所代码：COR），价值约为 1,655,000 美元，具体情况在其向美国证券交易委员会提交的 13F 文件中披露。其他机构投资者也调整了他们在 Cencora 的持股。分析师们提高了该股票的目标价格，普遍评级为 “适度买入”，平均目标价格为 306.91 美元。Cencora 报告的季度每股收益为 4.42 美元，超出预期，并宣布季度股息为 0.55 美元，反映出 0.76% 的收益率</p>

<p>Procyon Advisors LLC purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,951 shares of the company's stock, valued at approximately $1,655,000.</p>
<div class="lb-trans"><p>Procyon Advisors LLC 在第一季度购买了 Cencora, Inc. (NYSE:COR - 免费报告) 的新股份，根据其最近向证券交易委员会 (SEC) 提交的 13F 文件。该公司购买了 5,951 股公司股票，价值约为 1,655,000 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
</div><p>Other institutional investors also recently bought and sold shares of the company. Whittier Trust Co. lifted its holdings in Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after acquiring an additional 44 shares during the period. Shepherd Financial Partners LLC increased its holdings in shares of Cencora by 0.9% in the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after purchasing an additional 46 shares in the last quarter. WASHINGTON TRUST Co increased its holdings in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares in the last quarter. JFS Wealth Advisors LLC lifted its stake in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. boosted its holdings in Cencora by 1.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after buying an additional 47 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者最近也买卖了该公司的股票。Whittier Trust Co. 在第四季度将其在 Cencora 的持股增加了 0.6%。Whittier Trust Co. 目前拥有 7,856 股公司股票，价值 1,765,000 美元，在此期间又增持了 44 股。Shepherd Financial Partners LLC 在第四季度将其在 Cencora 的持股增加了 0.9%。Shepherd Financial Partners LLC 目前拥有 5,441 股公司股票，价值 1,223,000 美元，在上个季度又购买了 46 股。WASHINGTON TRUST Co 在第四季度将其在 Cencora 的持股增加了 37.7%。WASHINGTON TRUST Co 目前拥有 168 股公司股票，价值 38,000 美元，在上个季度又购买了 46 股。JFS Wealth Advisors LLC 在第四季度将其在 Cencora 的持股增加了 63.0%。JFS Wealth Advisors LLC 目前拥有 119 股公司股票，价值 27,000 美元，在此期间又购买了 46 股。最后，Cullen Frost Bankers Inc. 在第四季度将其在 Cencora 的持股增加了 1.1%。Cullen Frost Bankers Inc. 目前拥有 4,463 股公司股票，价值 1,003,000 美元，在上个季度又购买了 47 股。97.52% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages have issued reports on COR. Robert W. Baird increased their target price on shares of Cencora from $314.00 to $350.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, May 8th. Citigroup raised their price objective on Cencora from $330.00 to $355.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, May 8th. Bank of America boosted their target price on Cencora from $270.00 to $285.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, April 11th. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. Finally, Wells Fargo &amp; Company raised Cencora from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and lifted their price target for the stock from $274.00 to $337.00 in a research note on Tuesday. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $306.91.</p>
<div class="lb-trans"><p>多家券商对 COR 发布了报告。Robert W. Baird 将 Cencora 的目标价格从 314.00 美元上调至 350.00 美元，并在 5 月 8 日的报告中给予该公司 “跑赢大盘” 的评级。花旗集团将 Cencora 的目标价格从 330.00 美元上调至 355.00 美元，并在 5 月 8 日的研究报告中给予该公司 “买入” 评级。美国银行将 Cencora 的目标价格从 270.00 美元上调至 285.00 美元，并在 4 月 11 日的研究报告中给予该股票 “中性” 评级。摩根士丹利在 4 月 15 日的研究报告中设定了 Cencora 的 288.00 美元价格目标。最后，富国银行将 Cencora 的评级从 “等权重” 上调至 “超配”，并在周二将该股票的目标价格从 274.00 美元上调至 337.00 美元。一位分析师对该股票给予了持有评级，十位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价格为 306.91 美元。</p>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票上涨：WBA 可能是强劲买入的 4 个理由</li>
</ul>
</div><p><strong>Read Our Latest Report on COR</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 COR 的最新报告</strong></p>
</div><h2>Cencora Stock Up 0.2%</h2>
<div class="lb-trans"><h2>Cencora 股票上涨 0.2%</h2>
</div><p>Shares of NYSE:COR opened at $289.01 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market capitalization of $56.02 billion, a P/E ratio of 41.11, a P/E/G ratio of 1.31 and a beta of 0.58. Cencora, Inc. has a 52-week low of $218.65 and a 52-week high of $309.35. The stock's fifty day simple moving average is $286.29 and its 200-day simple moving average is $260.15.</p>
<div class="lb-trans"><p>NYSE:COR 的股票在周五开盘价为 289.01 美元。该公司的速动比率为 0.54，流动比率为 0.92，债务与股本比率为 16.40。该公司的市值为 560.2 亿美元，市盈率为 41.11，市盈率/增长比率为 1.31，贝塔值为 0.58。Cencora, Inc. 的 52 周低点为 218.65 美元，52 周高点为 309.35 美元。该股票的 50 日简单移动平均线为 286.29 美元，200 日简单移动平均线为 260.15 美元。</p>
</div><ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma 是重新崛起的仿制药的投资方式</li>
</ul>
</div><p>Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same period in the prior year, the firm earned $3.80 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Cencora (NYSE:COR - 获取免费报告) 最近在 5 月 7 日星期三发布了其财报。该公司报告每股收益 (EPS) 为 4.42 美元，超过分析师共识预期的 4.07 美元，超出 0.35 美元。Cencora 的净利润率为 0.46%，股本回报率为 328.62%。该公司在本季度的收入为 755 亿美元，而分析师预期为 754.1 亿美元。在去年同期，该公司每股收益为 3.80 美元。该公司的季度收入同比增长 10.3%。作为一个整体，股票研究分析师预测 Cencora, Inc. 在当前财政年度将发布 15.37 美元的每股收益。</p>
</div><h2>Cencora Announces Dividend</h2>
<div class="lb-trans"><h2>Cencora 宣布分红</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.76%. Cencora's dividend payout ratio (DPR) is presently 25.52%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，已于 6 月 2 日星期一支付。5 月 16 日星期五的登记股东获得了 0.55 美元的分红。除息日期为 5 月 16 日星期五。这代表着每年 2.20 美元的分红，收益率为 0.76%。Cencora 的分红支付比率 (DPR) 目前为 25.52%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares of the company's stock, valued at $5,241,249.24. This represents a 9.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,253 shares of company stock valued at $11,102,417 in the last quarter. 10.80% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席会计官 Lazarus Krikorian 于 3 月 10 日星期一出售了 2,000 股公司股票。股票以平均价格 260.06 美元出售，总交易额为 520,120.00 美元。交易完成后，首席会计官现在拥有 20,154 股公司股票，价值 5,241,249.24 美元。这代表着其持股减少了 9.03%。该交易已在向 SEC 提交的法律文件中披露，文件可通过此链接获取。此外，董事长 Steven H. Collis 于 4 月 22 日星期二出售了 14,579 股公司股票。股票以平均价格 281.81 美元出售，总交易额为 4,108,507.99 美元。交易完成后，董事长现在拥有 315,913 股公司股票，价值约 89,027,442.53 美元。此次交易使其持股减少了 4.41%。该交易的披露信息可以在此处找到。内部人士在上个季度共出售了 40,253 股公司股票，价值 11,102,417 美元。10.80% 的股票目前由公司内部人士持有。</p>
</div><h2>Cencora Profile</h2>
<div class="lb-trans"><h2>Cencora 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p>
<div class="lb-trans"><p>Cencora, Inc. 采购和分销药品。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代地点药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配备和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>3 Stocks Getting Rare Double Upgrades From Analysts</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>This Banking Giant Just Got a $90 Price Target Upgrade</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Cencora</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>大规模石油供应下降可能意味着这三只能源股的上涨空间</li>
<li>经纪排名在股票选择中的重要性</li>
<li>三只股票获得分析师罕见的双重升级</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>这家银行巨头刚刚获得了 90 美元的目标价上调</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cencora 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cencora 并不在名单上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cencora 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Procyon Advisors LLC 购入了 5,951 股 Cencora, Inc.（NYSE 代码：COR）的股票